Cargando…
Clinical progression of patients with COVID-19 in Lagos State, Nigeria
BACKGROUND: The majority of COVID-19 research has been devoted to characterizing the epidemiology and early clinical aspects of the virus. In Lagos, Nigeria, we looked at the temporal progression of COVID-19 patients. We included 1337 confirmed COVID-19 cases in our study from February 27th to March...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418277/ https://www.ncbi.nlm.nih.gov/pubmed/34514172 http://dx.doi.org/10.1186/s41231-021-00099-w |
_version_ | 1783748545837268992 |
---|---|
author | Mbagwu, JP. C. Olajugba, J. O. James-Okoro, Paula-Peace Blessing, Obidike |
author_facet | Mbagwu, JP. C. Olajugba, J. O. James-Okoro, Paula-Peace Blessing, Obidike |
author_sort | Mbagwu, JP. C. |
collection | PubMed |
description | BACKGROUND: The majority of COVID-19 research has been devoted to characterizing the epidemiology and early clinical aspects of the virus. In Lagos, Nigeria, we looked at the temporal progression of COVID-19 patients. We included 1337 confirmed COVID-19 cases in our study from February 27th to March 27th 2020. Of the 1337 patients enrolled, the median age was 50 years old, and 800 (59.83%) were male while 537 (40.16%) were female. METHOD: In symptomatic patients, the time from the beginning of signs to admission was 4 (2–7) days. Fever occurred in 217 (16.2%) while cough occurred in 211(15.78%) patients respectively. Patients were given 5–6 treatment, including nutrition support, supplementary oxygen, and antiviral medicines (e.g., Remdesivir, dexamethasone) in a limited percentage of cases. The assessed median period of infection in all patients was 10 days after the start of symptoms (95 confidential intervals [CIs]: 8–11 days). The duration of fever was slightly longer in patients admitted to intensive care units (ICU) than in those who were not (31 days versus 9 days, respectively, P < 0.003). RESULTS: On day 7 after the onset of symptoms, radiological deterioration of the original picture was found in 500 (37.39%) patients. On day 13, 154 of these patients (94.5%) showed signs of radiological improvement. The average time it took for upper respiratory tract samples to test negative for reverse transcriptase PCR was 10 days (90 percent confidence interval: 10–12 days). Virus clearance was more significant in ICU patients than in non-ICU patients (P < 0.003). CONCLUSIONS: Community members should continue to adhere to the recommended methods of preventing the spread of COVID-19 infection and patients should seek care early to reduce the risk of mortality associated with the infection as rapidly as possible. |
format | Online Article Text |
id | pubmed-8418277 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84182772021-09-07 Clinical progression of patients with COVID-19 in Lagos State, Nigeria Mbagwu, JP. C. Olajugba, J. O. James-Okoro, Paula-Peace Blessing, Obidike Transl Med Commun Research BACKGROUND: The majority of COVID-19 research has been devoted to characterizing the epidemiology and early clinical aspects of the virus. In Lagos, Nigeria, we looked at the temporal progression of COVID-19 patients. We included 1337 confirmed COVID-19 cases in our study from February 27th to March 27th 2020. Of the 1337 patients enrolled, the median age was 50 years old, and 800 (59.83%) were male while 537 (40.16%) were female. METHOD: In symptomatic patients, the time from the beginning of signs to admission was 4 (2–7) days. Fever occurred in 217 (16.2%) while cough occurred in 211(15.78%) patients respectively. Patients were given 5–6 treatment, including nutrition support, supplementary oxygen, and antiviral medicines (e.g., Remdesivir, dexamethasone) in a limited percentage of cases. The assessed median period of infection in all patients was 10 days after the start of symptoms (95 confidential intervals [CIs]: 8–11 days). The duration of fever was slightly longer in patients admitted to intensive care units (ICU) than in those who were not (31 days versus 9 days, respectively, P < 0.003). RESULTS: On day 7 after the onset of symptoms, radiological deterioration of the original picture was found in 500 (37.39%) patients. On day 13, 154 of these patients (94.5%) showed signs of radiological improvement. The average time it took for upper respiratory tract samples to test negative for reverse transcriptase PCR was 10 days (90 percent confidence interval: 10–12 days). Virus clearance was more significant in ICU patients than in non-ICU patients (P < 0.003). CONCLUSIONS: Community members should continue to adhere to the recommended methods of preventing the spread of COVID-19 infection and patients should seek care early to reduce the risk of mortality associated with the infection as rapidly as possible. BioMed Central 2021-09-04 2021 /pmc/articles/PMC8418277/ /pubmed/34514172 http://dx.doi.org/10.1186/s41231-021-00099-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Mbagwu, JP. C. Olajugba, J. O. James-Okoro, Paula-Peace Blessing, Obidike Clinical progression of patients with COVID-19 in Lagos State, Nigeria |
title | Clinical progression of patients with COVID-19 in Lagos State, Nigeria |
title_full | Clinical progression of patients with COVID-19 in Lagos State, Nigeria |
title_fullStr | Clinical progression of patients with COVID-19 in Lagos State, Nigeria |
title_full_unstemmed | Clinical progression of patients with COVID-19 in Lagos State, Nigeria |
title_short | Clinical progression of patients with COVID-19 in Lagos State, Nigeria |
title_sort | clinical progression of patients with covid-19 in lagos state, nigeria |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418277/ https://www.ncbi.nlm.nih.gov/pubmed/34514172 http://dx.doi.org/10.1186/s41231-021-00099-w |
work_keys_str_mv | AT mbagwujpc clinicalprogressionofpatientswithcovid19inlagosstatenigeria AT olajugbajo clinicalprogressionofpatientswithcovid19inlagosstatenigeria AT jamesokoropaulapeace clinicalprogressionofpatientswithcovid19inlagosstatenigeria AT blessingobidike clinicalprogressionofpatientswithcovid19inlagosstatenigeria |